Findings
========

Activation of the epidermal growth factor receptor (EGFR) oncoprotein, a member of the ErbB family of receptor tyrosine kinases, is among the most common oncogenic driving events in human cancer \[[@B1]\]. Genomic mechanisms for activating the *EGFR* gene include nucleotide substitutions and in-frame insertions/deletions of the kinase domain in lung adenocarcinoma and papillary thyroid carcinomas, and multi-exonic deletions (exons 2 through 7: EGFR variant III or vIII), nucleotide substitutions of the extracellular domain and carboxyl terminal deletions in glioblastoma \[[@B2]-[@B6]\]. *EGFR* is also activated by high-copy amplifications in many epithelial cancer types, prominently in lung and upper gastrointestinal carcinomas as well as glioblastoma and head and neck cancer \[[@B7]-[@B10]\]. Furthermore, EGFR protein is over-expressed in many cancers even without evidence of focused genomic alteration, as observed in many cases of colorectal carcinoma where *EGFR* kinase domain mutations were found in only 3 out of 224 cases, 1.3% subjected to whole exome sequencing \[[@B11],[@B12]\]. Given the elevated expression and genomic alterations present in EGFR, multiple cancer therapies have targeted EGFR, as both its kinase activity and its dependence on extracellular ligand signaling have rendered EGFR vulnerable to therapeutic intervention. FDA-approved EGFR targeted inhibitors include the low-molecular-weight ATP-competitive kinase inhibitors, such as gefitinib and erlotinib, and humanized monoclonal antibodies directed against the extracellular domain, notably cetuximab and panitumumab \[[@B13]\]. Although high-level expression of EGFR ligands and/or increased EGFR gene copy numbers may be predictive markers for antitumor response by cetuximab in colon cancer \[[@B14]-[@B16]\], and patients with RAS driven cancers are known not to benefit from cetuximab treatment, a clear molecular explanation of cancer response to cetuximab has remained elusive.

Genomic studies identify G724S mutant in colorectal carcinomas
==============================================================

Colorectal adenocarcinoma has been a classic model to study the progressive accumulation of genomic lesions leading to cellular transformation. Key genomic features of these tumors involve inactivation of tumor suppressors such as *APC, TP53* and *SMAD4* and mutational activation of oncogenes including *KRAS, NRAS, BRAF* and *PIK3CA*\[[@B17]\]. Given the role of cetuximab in therapy of these cancers, initial efforts to identify activating EGFR mutations identified few such events, though potentially activating events such as G719S were seen \[[@B18]\]. More recent reports have also identified potentially mutations of *ERBB3*\[[@B19]\] and amplifications and mutations of *ERBB2* in CRC \[[@B12],[@B20]\]. We have previously reported whole genome sequence analysis of nine colorectal carcinoma/normal pairs,leading to the identification of activating translocations of *TCF7L2* and of the association of *Fusobacterium nucleatum* with colorectal carcinomas \[[@B21],[@B22]\]. Here, we report genomic analysis of a tenth anonymized case of colorectal carcinoma. Whole genome sequencing was performed on the genomic DNA from colorectal carcinoma tissue and adjacent non-neoplastic colonic tissue to a median coverage of 32.5x and 34.2x coverage, respectively, with 86.8% of the genome sequenced to adequate depth for mutation calling.

An analysis of somatic genome structural alterations by comparison of tumor-derived and non-neoplastic derived sequences identified 63 somatic structural rearrangements, including a deletion of the *APC* tumor suppressor gene (Figure  [1](#F1){ref-type="fig"}A, Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1A, and Additional file [2](#S2){ref-type="supplementary-material"}: Table S1). Comparison of nucleotide sequences between the colorectal tumor and normal colon identified an overall mutation rate of 6.7 mutations/Mb including 18,401 somatic nucleotide substitutions, and 983 somatic insertions and deletions of \< 37 bases (Figure  [1](#F1){ref-type="fig"}B and Additional file [3](#S3){ref-type="supplementary-material"}: Table S2). As observed in other colorectal cancers \[[@B21],[@B23],[@B24]\], mutation analysis identified a marked elevation in the rate of C to T transitions at CpG dinucleotides (82/Mb). Analysis of non-synonymous coding mutations revealed a total of 119 alterations in 116 genes (Additional file [4](#S4){ref-type="supplementary-material"}: Table S3). Prominent mutations included a somatic R175H substitution in the *TP53* tumor suppressor gene and a somatic G724S substitution in the *EGFR* oncogene (Figure  [1](#F1){ref-type="fig"}B and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1B). Somatic mutations of common colorectal adenocarcinoma oncogenes *KRAS, BRAF, NRAS* and *PIK3CA*\[[@B23]\] were not detected.

![**Identification of a somatic*EGFR*mutation in colorectal adenocarcinoma via whole genome sequencing. (A)** Depiction of the somatic structural rearrangements in this colorectal cancer genome by a Circos plot. The chromosomes are depicted along the circle with somatic rearrangements depicted in purple (interchromosomal) and green (intrachromosomal), including a deletion at the *APC* tumor suppressor locus. **(B)** Depiction of numbers of candidate mutations and non-synonymous alterations in coding genes, and mutations in known cancer genes, *TP53* and *EGFR*. **(C)** Schematic of somatic *EGFR* mutations found in glioblastoma (green lettering), lung adenocarcinoma (blue lettering) and colorectal adenocarcinoma (red lettering), with insertions and deletions above the domain structure, and substitution mutations below the domain structure indicated by red dots.](1476-4598-13-141-1){#F1}

The absence of both *KRAS* and *BRAF* mutations are common features seen in colorectal cancers that are responsive to cetuximab \[[@B25],[@B26]\], thus making the *EGFR* mutation in this case of particular interest. The somatic G724S mutation in *EGFR* occurs at the final glycine of the GxGxxG nucleotide-binding motif that is essential for ATP binding and is conserved among all protein kinases (Figure  [1](#F1){ref-type="fig"}C) \[[@B27],[@B28]\]. Substitution of EGFR G719, the first residue of this motif, to serine, cysteine, or alanine, has been observed in lung adenocarcinomas (\~1%), and one G719S mutant and four G724S mutants have been reported in colorectal carcinomas that were sequenced for EGFR (Figure  [1](#F1){ref-type="fig"}C) \[[@B18],[@B29]\] (COSMIC database). In addition, these EGFR mutations were found to be mutually exclusive with well known *KRAS*, *BRAF* and *PIK3CA* oncogenic driver mutations, demonstrating their potential role in tumorigenesis (COSMIC database).

Colon-cancer derived G719S and G724S mutants are oncogenic and sensitive to cetuximab
=====================================================================================

To determine whether the G724S mutant is oncogenic and to evaluate its pharmacologic sensitivity, we generated this mutant *in vitro* and retrovirally transduced it into NIH-3T3 cells. While wild-type EGFR expressing NIH-3T3 cells form colonies in soft agar only in the presence of ligand, NIH-3T3 cells that express EGFR G724S form colonies in the absence of exogenous ligand, as do the lung and colon cancer-derived G719S mutants (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S2A) \[[@B30]\]. Furthermore, both G719S and G724S mutants undergo constitutive tyrosine-phosphorylation, which is further increased by EGF treatment, whereas phosphorylation of wild-type EGFR requires induction by EGF (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S2B). These data demonstrate that colon-cancer derived G719S and G724S mutants are oncogenically active in the absence of ligand stimulation.

To test whether G719S and G724S EGFR mutants are cetuximab-sensitive *in vitro*, we ectopically expressed these mutants in Ba/F3 cells, rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling \[[@B31]\]. Ba/F3 cells expressing the colon-cancer derived G724S mutant and the lung/colon cancer-derived G719S mutant showed sensitivity to cetuximab with an IC~50~ value of \~ 0.3 μg/ml (Figure  [2](#F2){ref-type="fig"}A). In contrast to their high cetuximab sensitivity, Ba/F3 cells dependent on EGFR G719S and G724S mutants were only moderately sensitive to erlotinib with an IC~50~ value of \~ 0.3 μM (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S3A), consistent with previous reports on G719X mutants *in vitro* and in lung cancer clinical trials \[[@B30]-[@B33]\] and with the failure of a previously identified patient with EGFR G724S mutant colorectal cancer to respond to gefitinib \[[@B29]\].

![**Pharmacological effects of cetuximab against oncogenic G719S and G724S mutants*in vitro*and*in vivo.*(A)** Cetuximab suppresses the growth of Ba/F3 cells dependent upon the G719S and G724S mutants, but not control cells. Ba/F3 cells transformed with the indicated EGFR mutants were treated with cetuximab at the concentrations indicated and assayed for viability after 72 hours of drug treatment. The results are indicated as mean +/- SD of sextuplicate wells and are representative of three independent experiments **(B** and **C)** Cetuximab is effective against SW48 (EGFR G719S mutant)-induced tumors but not HCT8 (KRAS G13D mutant) induced-tumors in xenografted mice. BALB/c-nu/nu mice (6--8 weeks of age) were injected subcutaneously to the flank with 0.5 \~ 1x10^7^ SW48 or HCT8 cells in 150 \~ 200 μl of PBS. Tumor sizes were measured two times a week using a Vernier caliper and tumor volumes were calculated according to the formula of (short diameter)^2^ x (long diameter)/2. When tumor volume reached around 100 \~ 150 mm^3^, mice were randomized into each group. After confirming that mean tumor volumes were not statistically different between two groups, mice were administered either with PBS or cetuximab (1 mg/mouse) intra-peritoneally twice a week.](1476-4598-13-141-2){#F2}

In order to further examine the efficacy of cetuximab, we expanded our studies by generating xenograft mouse models with either SW48 or HCT8 colon cancer cells, which harbor either *EGFR* G719S or *KRAS* G13D mutation, respectively. Here, we found that consistent with *in vitro* response (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S3B), cetuximab treatment dramatically suppressed tumor formation driven by SW48 cells (Figure  [2](#F2){ref-type="fig"}B), suggesting the anti-tumor effect of cetuximab against tumors harboring EGFR G719S mutant. In contrast, cetuximab treatment was ineffective for the tumors driven by HCT8, which is consistent with the previous findings that KRAS-mutant tumors are insensitive to cetuximab (Figure  [2](#F2){ref-type="fig"}C). Taken together, we found that G719S and G724S mutants are oncogenic in the absence of ligand stimulation and effectively respond to cetuximab *in vivo* and *in vitro*.

Asymmetric dimerization is required for oncogenic activity of G719S and G724S mutant
====================================================================================

Recently, we reported that a subset of lung cancer-derived oncogenic EGFR mutants such as L858R require asymmetric dimerization for biochemical activation and oncogenic transforming activity, meaning that their oncogenic ability depend on formation of an EGFR homodimer in which two distinct regions of the two molecule dimerize \[[@B34]\]. By contrast, we showed that other EGFR mutants are oncogenic without the requirement for dimerization, including the gefitinib-resistant exon 20 insertion mutant and the T790M mutant \[[@B34]\]. Furthermore, we found that dimerization-dependent L858R mutant shows a dramatic response to cetuximab, whereas tumors driven by dimerization-independent mutants such as T790M are resistant to the antibody, suggesting that there is a close correlation between dimerization dependency of lung cancer-derived oncogenic mutant EGFR and pharmacological effects of cetuximab \[[@B34]\]. Given that colon cancer-derived G719S and G724S mutants are sensitive to cetuximab, we sought to examine whether oncogenic potential of these mutants are dependent on the asymmetric dimerization like lung cancer-derived L858R mutant.

To test the hypothesis that cetuximab sensitivity of G719S and G724S mutants is a function of their dimerization dependence, we generated G719S and G724S mutants with compound substitution mutations at the dimerization interface in the N-lobe or C-lobe that disrupt the asymmetric dimerization of EGFR \[[@B35]\]. Specifically, we generated epitope-tagged EGFR expression constructs that combined a receiver-impairing mutation (L704N) and/or an activator-impairing mutation (I941R) with oncogenic G719S and G724S mutants. The single or compound EGFR mutants were expressed in NIH-3T3 cells by retroviral transduction, and the EGFR mutant-expressing cells were assayed for their ability to grow in soft agar. In this system, the transforming ability of dimerization-dependent mutants is predicted to be abolished by *cis* mutation of the L704 or I941 mutations. Furthermore, co-expression of the L704N and I941R mutant forms, in contrast, is predicted to restore transforming ability that is dimerization-dependent, because the two mutant forms can heterodimerize. Therefore, this experiment allows us to test whether specific EGFR kinase domain mutants can induce cellular transformation in a dimerization dependent or independent fashion.

Dimerization-impairing *cis* mutations in EGFR, L704N and I941R, significantly reduced the ability of the cetuximab-sensitive G719S and G724S mutants to promote colony formation upon retroviral transduction (Figure  [3](#F3){ref-type="fig"}A and B, L704N or I941R); colony-forming activity was partially or completely restored by co-expression of the L704N and I941R mutants in *trans* (Figure  [3](#F3){ref-type="fig"}A and B, L704N&I941R). Consistent with these results, we found that constitutive and EGF-inducible autophosphorylation of the G719S and G724S mutants (Figures  [3](#F3){ref-type="fig"}C and D, lanes 1 and 2), is attenuated by the introduction of L704N and I941R dimerization-impairing mutations (Figures  [3](#F3){ref-type="fig"}C and D, lanes 3, 4, 5, and 6). Furthermore, receptor phosphorylation is partially rescued by co-expression of either G719S/L704N or G719S/I941R mutants or the cognate combination in a G724S mutant background (Figure  [3](#F3){ref-type="fig"}C and D, lanes 7 and 8). Taken together, these data suggest that colon cancer-derived cetuximab-sensitive G719S and G724S mutants acquire their oncogenic potentials following asymmetric dimerization, respectively, which are similar to lung-cancer derived L858R mutant \[[@B35]\]. Furthermore, these results are consistent with our model that EGFR variants that are dependent on dimerization can be inhibited by cetuximab.

![**Dimerization disruption has effects on the transforming activity of G719S and G724S EGFR proteins.(A** and **B)** G719S and G724S mutants are dependent on asymmetric dimerization for their transforming potential. NIH-3T3 cells expressing the indicated EGFR mutants with or without receiver-impairing (L704N) or/and activator-impairing (I941R) mutations were assayed for anchorage-independent growth in soft agar. The bar graph depicts the relative number of colonies in the dimerization-defective mutants normalized to the number of colonies formed by cells expressing the respective parental mutants (n = 3, mean + SD). **(C** and **D)** Ligand-induced and constitutive tyrosine-phosphorylation is abrogated on dimerization-impaired compound mutants of cetuximab-sensitive EGFR mutants. Whole cell lysates from the same cells analyzed in Figure  [3](#F3){ref-type="fig"}A and B expressing G719S **(C)**, and G724S **(D)** mutants with or/and without dimerization-impairing mutations (L704N or I941R) in the absence or presence of EGF treatment for 15 minutes (25 ng/ml) were subjected to immunoblotting with antibodies against phospho-tyrosine (4G10) and EGFR.](1476-4598-13-141-3){#F3}

In summary, our findings suggest that *EGFR* mutation may underlie at least some cases of cetuximab responsiveness in colorectal carcinoma. While *EGFR* mutation has historically been believed to be rare in colorectal carcinomas, whole exome sequencing published through The Cancer Genome Atlas identified somatic non-synonymous coding *EGFR* mutations in 10 of 224 colorectal carcinoma cases (or 4.5%) \[[@B12]\]. While many such mutations may be passenger alterations that do not activate EGFR signaling, these results do speak to the potential for mutational activation of EGFR to result in susceptibility to anti-EGFR antibodies in a small fraction of CRC cases. Indeed, the recent demonstration of secondary somatic mutation in the EGFR extracellular domain conferring acquired resistance to cetuximab \[[@B36]\] is consistent with attribution of responses to cetuximab to EGFR blockade. Anti-EGFR therapy in metastatic colorectal cancer has been reserved for second-line therapy after failure of initial empiric chemotherapy but is now increasingly also used as part of first-line therapy for RAS wild-type patients. As genomic diagnostics enter into routine clinical practice, patients whose CRCs harbor potentially oncogenic *EGFR* mutations will be identified, including those at codons 719 and 724. These results suggest that in such patients, therapeutic approaches utilizing EGFR-directed antibody as part of their initial therapy should be evaluated given the greater potential dependence on EGFR signaling in these patients.
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